Editor's Note: The Fierce Life Sci weekly digest will not publish next Friday, for the holiday season. We'll see you in the new year, and be back in your inboxes January 3, 2025.
Sort through the noise and hear from Washington Insiders. This session will offer key insights into the economic and political landscape, guiding your company on how best to prepare for and respond to potential changes in funding opportunities and compliance requirements. Register now.
After the recent release of two independent studies suggested the use of Ozempic increases patients' chances of developing a rare eye disorder, the European Union has decided to investigate the issue, according to a report from Reuters.
Bristol Myers Squibb has terminated cell therapy pacts with two biotechs amid "ongoing portfolio prioritization efforts” within the Big Pharma, one of the affected companies said.
The FDA has sent complete response letters to Johnson & Johnson and AstraZeneca, rejecting J&J's application for subcutaneous Rybrevant and AZ's bid for a full approval of Andexxa.
Discover how next-gen Protein A resins and multi-column chromatography can help biomanufacturers optimize costs, enhance purification efficiency, and improve productivity. Learn practical strategies and explore real-world case studies showcasing advanced solutions for scalable, high-throughput processes. Register now.
After pulling off a surprise third-quarter beat and full-year guidance raise amid shareholder activism earlier this year, Pfizer now expects its 2025 revenues to come in the same range as in 2024.
In a day that already included discontinuations from Roche and Foghorn Therapeutics, Merck & Co. rounded out Monday with the termination of two late-stage cancer assets.
The ubiquity of GLP-1 agonists in popular culture may be negatively affecting patients’ perceptions and use of the medications for weight management, according to a new survey of doctors around the world.
As Bavarian Nordic works to increase global access to its mpox vaccine, the company has inked a manufacturing licensing pact with the Serum Institute of India (SII) to produce MVA-BN for the Indian market.
As human cases of avian influenza slowly tick up amid the outbreak in U.S. dairy cattle, the Centers for Disease Control and Prevention and Moderna have teamed up to design an mRNA vaccine for the current variant that successfully protected ferrets from succumbing to the virus.
In today’s fast-paced and uncertain landscape, pharmaceutical manufacturers face complex challenges that demand agile and integrated planning across all business functions. Join us for an exclusive webinar on how to leverage Integrated Business Planning (IBP) to enable a more connected, data-driven approach to planning. Register now.
Learn how to evaluate quality documentation to help you select the right raw materials at early decision points for your cell-based manufacturing processes.
We interviewed 14 R&D biopharma leaders on the critical success factors for building a Best Practice R&D organization. This report shares what we learned.
Presented by Blue Matter, strategic consultants in the life sciences
